Last reviewed: July 1, 2026
Last updated: July 1, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both Mounjaro and Wegovy have demonstrated significant weight loss results in clinical trials, yet they work through different biological pathways. Mounjaro, containing tirzepatide, activates both GLP-1 and GIP receptors, while Wegovy, containing semaglutide, targets the GLP-1 receptor alone. Choosing between them depends on your body's peptide responsiveness, medical history, and treatment goals.
How Mounjaro and Wegovy Work Differently in Your Body
Mounjaro's active ingredient, tirzepatide, functions as a dual receptor agonist that stimulates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) pathways. This dual action increases insulin secretion when blood sugar rises, suppresses glucagon release, and signals satiety in the brain more comprehensively than single-pathway medications. Wegovy contains semaglutide, which activates only the GLP-1 receptor, slowing gastric emptying and promoting fullness through one primary signaling route.
The distinction matters because individual genetic variation affects how efficiently your body responds to each pathway. Some people achieve superior weight loss through dual activation, while others respond equally well to single-pathway therapy. PlexusDx's Precision Peptide Genetic Test identifies key variants in the GLP1R and GIPR genes that predict your personalized response to tirzepatide versus semaglutide, guiding treatment selection before you commit to medication.
Clinical Weight Loss Results: Mounjaro Versus Wegovy
Mounjaro demonstrated average weight loss of 21.7% of baseline body weight at the highest dose in the SURMOUNT-2 trial over 72 weeks, while Wegovy showed approximately 17.4% weight loss in the STEP trials using the same timeframe. The difference reflects tirzepatide's dual-receptor mechanism providing additional metabolic advantage in the majority of studied populations. However, these are population averages; individual responses vary significantly based on genetics, lifestyle adherence, and baseline metabolic function.
The higher average efficacy of tirzepatide does not guarantee superior results for every patient. Approximately 30% of people respond equally well to semaglutide monotherapy, and some experience better tolerability or fewer side effects with the single-pathway approach. Your genetic profile, particularly variants in the GLP1R, GIPR, FTO, and MC4R genes, substantially influences whether you belong to the tirzepatide-responsive or semaglutide-responsive population.
Cost Comparison and Access Through PlexusDx
PlexusDx offers compounded tirzepatide injection starting at $249 per month with no flat per-compound pricing increases—your dose may need to go up, your price won't. Compounded semaglutide injection begins at $149 per month with the same flat-rate commitment structure. Both medications come from licensed 503A compounding pharmacies and are available across all 50 states without insurance requirements or membership fees.
Neither brand-name Mounjaro nor brand-name Wegovy qualify for PlexusDx's service model, but high-quality compounded versions provide bioequivalent therapeutic action at transparent, predictable monthly costs. HSA and FSA accounts cover PlexusDx medications, reducing out-of-pocket expenses further. Patients can also add the Precision Peptide Genetic Test for $99 after their first treatment month to confirm their medication matches their genetic predispositions.
Side Effects, Tolerability, and Long-Term Sustainability
Common side effects for both medications include nausea, vomiting, diarrhea, and constipation, occurring most frequently during dose escalation phases. Tirzepatide's dual-pathway action sometimes produces more pronounced nausea initially, though many patients adapt as their body adjusts. Semaglutide generally shows slightly milder early gastrointestinal effects in some populations, but sustained efficacy and tolerability depend more on individual physiology than drug choice alone.
Long-term weight maintenance requires ongoing medication use; discontinuation typically results in weight regain within months. Both tirzepatide and semaglutide users report improved cardiometabolic markers, reduced inflammation, and sustained weight loss when treatment continues. The optimal choice balances efficacy, side effect profile, cost, and your genetic responsiveness—factors PlexusDx integrates through genetic testing and personalized protocol selection.
Personalized Selection: Genetic Testing Guides Your Decision
PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and identifies variants in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 that predict your individual response pattern to tirzepatide, semaglutide, or combination protocols. This genetic data reveals whether your weight regulation favors dual-receptor activation or responds optimally to single-pathway therapy, removing guesswork from medication selection.
Patients beginning PlexusDx treatment can add genetic testing after their first month, allowing them to confirm their current medication is aligned with their genetic predispositions or adjust to a better-matched protocol. This precision approach transforms weight loss from trial-and-error experimentation into biology-informed decision-making, maximizing efficacy while minimizing wasted time on suboptimal medications.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes fewer side effects, Mounjaro or Wegovy?
Tolerability varies by individual genetics and prior GLP-1 exposure. Semaglutide (Wegovy) often produces milder initial nausea, while tirzepatide (Mounjaro) may trigger stronger early GI symptoms due to dual activation. PlexusDx's Precision Peptide Genetic Test identifies your likely tolerability profile before starting treatment, helping predict which medication your body will adjust to most comfortably.
Does Mounjaro work better than Wegovy for everyone?
Population studies show tirzepatide averages 4-5% greater weight loss, but approximately 30% of patients respond identically to semaglutide with equal or superior tolerability. Genetic variation in GLP1R and GIPR expression determines your individual response; some people achieve better results with semaglutide monotherapy. Genetic testing clarifies your predicted responder status before committing to either medication.
Can I get compounded Mounjaro or Wegovy through PlexusDx?
PlexusDx provides high-quality compounded tirzepatide injection starting at $249/month and compounded semaglutide injection starting at $149/month from licensed 503A pharmacies. These compounded versions deliver equivalent therapeutic action to brand-name medications at transparent, flat monthly rates with no insurance required. Both are HSA/FSA eligible across all 50 states.
What are the serious side effects I should watch for?
Rare but serious risks include pancreatitis, thyroid concerns, gallbladder issues, and hypoglycemia in insulin-using patients. Both tirzepatide and semaglutide require medical supervision; patients should report severe abdominal pain, vision changes, or persistent vomiting immediately. PlexusDx treatment always includes healthcare provider oversight to monitor safety and adjust protocols as needed.
How does genetic testing help me choose between these medications?
PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R that predict whether your metabolism favors dual-receptor (tirzepatide) or single-pathway (semaglutide) activation. This data eliminates guesswork, allowing you to select or switch to the medication genetically matched to your physiology, improving both efficacy and cost-effectiveness. Testing costs $99 after your first treatment month.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding How Many Doses Are in an Ozempic Pen
Is Wegovy the Best for Weight Loss? A Comprehensive Exploration